4 Wassim Abida, David Campbell, Akash Patnaik, et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study[J]. Clin Cancer Res, 2020, doi:10.1158/1078-0432.CCR-20...
4 Wassim Abida, David Campbell, Akash Patnaik, et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study[J]. Clin Cancer Res, 2020, doi:10.1158/1078-0432.CCR-20...
目前的一线药物治疗情况下，mCRCP 患者的中位总生存期为2-3年。BRCA1/2突变患者的预后较差(约占一线治疗mCRPC 患者的8-11% )。 PROfound、TRITON和 TRITON研究中已经证明了 PARP 抑制剂在雄激素受体通路抑制剂治疗后进展的HRR 突变的mCRPC 患者的总体生存益处。的三期临床试验(2022-2023) ，并纳入本分析:PROpel...
Poly(ADP‐ribose) Polymerase InhibitorProstate CancerOlaparibRucaparibBRCADNA Damage RepairHomologous Recombination RepairMismatch RepairMutationBiomarkerThe U.S. Food and Drug Administration (FDA) recently approved two poly-ADP ribose polymerase (PARP) inhibitors, olaparib and rucaparib, for treatment of ...
在转移性去势抵抗性前列腺癌(mCRPC,Metastatic Castration-Resistant Prostate Cancer)疗法的开发领域,阿斯利康、辉瑞和强生都瞄准了PARP(聚ADP-核糖聚合酶)抑制剂联合抗雄激素药物的策略,它们近期都公布了各自的III期数据,这无疑将成为一个潜在的重磅药物机会。要知道前列腺癌是男性第二常见的癌症,仅次于皮肤癌。
2.S.D. Fontaine, G.W. Ashley, P.J. Houghton, R.T. A very long-acting PARP inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models, Cancer Res. 81 (2021) 1076–1086. 3.Three withdrawals in advanced ovarian cancer spell trouble for PARP class;ENDPOINTS NEWS. ...
[4]Sayyid R,et al.PARP Inhibitor Plus AndrogenReceptor Pathway InhibitorCombinations for 1st Line mCRPC:A Systematic Review and Meta-Analysis.2024 EAU Abstract#A0635. [5]Agarwal N, Azad AA, Carles J,et al . Talazoparib pl...
[4]Sayyid R,et al.PARP Inhibitor Plus AndrogenReceptor Pathway InhibitorCombinations for 1st Line mCRPC:A Systematic Review and Meta-Analysis.2024 EAU Abstract#A0635. [5]Agarwal N, Azad AA, Carles J,et al . Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant ...
上世纪90年代开始,有研究将PARP抑制剂(PARP inhibitor,PARPi)用于提高放疗和化疗对肿瘤的抑制活性。理论上讲,由化疗药物或电离辐射诱导的癌细胞DNA单链断裂(SSBs)可能会被PARP依赖性机制修复,从而导致肿瘤细胞得以生存,而联用PARPi有望阻止DNA修复,导致细胞死亡[4-5]。但到目前为止,并没有PARP抑制剂与化疗或放疗连...
EP. 17: Recap: Recommendations for PARP Inhibitor Use in Prostate Cancer A. Oliver Sartor, MD December 28th 2021 A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer. EP. 18: Recap: Testing and Treating Metastatic Castration-Resistant Prosta...